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SUMMARY 
In recent years the nature of HIV infection has been dramatically transformed from an invariably fatal 
disease to a chronic disorder with a relatively benign course. Disease progression from HIV to AIDS 
and HIV-related mortality can be reduced effectively by several years of treatment with highly active 
antiretroviral therapy (HAART). For patients who do not have access to HAART, HIV infection 
continues to be a lethal disorder characterized by opportunistic infection with uncommon organisms 
(e.g. mycobacteria, fungi, parasites and viruses), as well as lethal malignancies such as Kaposi 
sarcoma, non-Hodgkin lymphoma and squamous cell carcinoma of the penis or cervix. In patients 
receiving HAART, urologic complications are likely to be caused by adverse effects of antiretroviral 
medication (e.g. indinavir urolithiasis) or disorders associated with aging, such as benign prostatic 
hyperplasia and prostate cancer. Prospective clinical trials have shown that adult male circumcision 
can reduce the rate of female to male HIV transmission by more than 50%; however, the 
development of preventive or curative modalities with 100% efficacy remains elusive. 
REVIEW CRITERIA 
A comprehensive PubMed search of the English-language literature published between January 1980 
and March 2008 was made for relevant articles using the Medical Subject Heading terms "HIV", 
"AIDS" and "urology" or "urological(al)" in various combinations. The reference lists of retrieved 
articles were assessed for additional articles. 
Keywords: AIDS, HIV, urologic complications 
 
INTRODUCTION 
HIV is a retrovirus that replicates rapidly and kills helper T cells, which are the body's main cellular 
defense against infection. HIV is spread through contact with blood, semen and vaginal secretions—
for example during homosexual or heterosexual intercourse, by use of contaminated needles or 
blood products, or from mother to child during birth or through breast feeding. 
AIDS refers to the disorder caused by HIV infection. AIDS usually occurs when CD4+ count falls below 
200 cells/mm3. The clinical course of the disease is characterized by recurrent infection by various 
uncommon opportunistic bacteria, fungi and viruses, which can involve any part of the urogenital 
system. Despite the aggressive nature of standard therapy, AIDS can have a rapidly fatal course in 
most patients. 
In the past decade, the increasing availability of antiretroviral drugs has helped combat HIV 
replication and has changed HIV infection from an almost invariably fatal disorder to just another 
chronic illness. HIV-positive patients who are treated with highly active antiretroviral therapy 
(HAART) have an almost normal life expectancy, and are now presenting with common urologic 
disorders that usually affect elderly people. Unfortunately, HAART is not readily available in many of 
the countries that have the highest prevalence of HIV infection—in these regions AIDS has retained 
its profile as a severely debilitating and eventually fatal disorder. 
1
Urologic disorders (Box 1) are often the first clinical signs that indicate possible HIV infection. In this 
Review we discuss the main urologic complications in patients with HIV and AIDS, including 
complications resulting from treatment. 
 
EPIDEMIOLOGY OF HIV AND AIDS 
 
WHO data show that the global prevalence of HIV infection has leveled off—39.5 million people were 
affected in 2006 and 33.2 million in 2007. Worldwide, 2.5 million people became newly infected in 
2007, and 2.1 million died of AIDS.1Although the incidence of new cases has leveled off, the total 
number of people living with HIV infection is increasing. 
Sub-Saharan Africa contains 10% of the world's population but accounts for less than 1% of the 
world's health expenditure. This region bears more than 70% of the global burden of HIV and AIDS, 
with an estimated 22.5 million people living with HIV.2 It is expected that the AIDS death toll in sub-
Saharan Africa will continue to rise due to inadequate prevention and reduced treatment efforts 
compared with other parts of the world; therefore, a substantial increase in the magnitude of the 
AIDS epidemic is expected during the course of the next 10 years.3 
In 2007, HIV incidence in Eastern Europe and Central Asia increased by more than 150%. In Vietnam 
HIV incidence more than doubled between 2000 and 2005, and Indonesia has the fastest growing 
epidemic.4 The prevalence of HIV continues to increase in the US, which currently has an estimated 
1.2 million people living with HIV; about 74% of cases are in adult men, and the epidemic continues 
to disproportionately affect African Americans.5, 6 
 
UROLOGIC COMPLICATIONS OF HIV AND AIDS 
RENAL DYSFUNCTION 
Acute renal failure in HIV-infected patients is common and is associated with advanced 
immunodeficiency.7 Kidney disease and subsequent renal failure is the fourth leading cause of death 
in HIV-positive patients.8 Renal dysfunction in patients with HIV can be caused by nephrotoxic 
medications such as antibiotics and antifungals, metabolic dysfunction and volume depletion as a 
result of chronic diarrhea, ureteral obstruction from malignancy, infections, and intrinsic diseases 
such as HIV-associated nephropathy (HIVAN), which occurs in 10–30% of patients with HIV. 
One-year mortality in patients with HIVAN is 50%; even in those being treated with HAART it is 
approximately 30%.8 HIVAN is characterized by acute decline in kidney function, high-grade 
proteinuria (more than 3.5 g of protein excreted per day), edema, hypertension and anemia, and is 
associated with CD4+ counts <350 cells/mm3. Renal ultrasound usually shows that the kidneys are of 
normal size but have increased echogenicity. Diagnosis of HIVAN is confirmed with renal biopsy. 
Histologic findings include focal segmental glomerulosclerosis, usually with tubulointerstitial 
nephritis.9 
In a single study from South Africa,10 renal biopsies in HIV-positive black patients showed that the 
main histologic categories of kidney disease were classic HIVAN (27%) and HIV-related 'immune 
complex kidney disease' (21%). Other glomerulonephritides included membranous disease, 
postinfectious disease, mesangial hyperplasia, and immunoglobulin A nephropathy. Overlapping 
clinical presentations prevented prebiopsy histologic predictions.10 Treatment of HIVAN includes 
HAART, corticosteroids, angiotensin-converting-enzyme inhibitors, and, eventually, renal 
replacement therapy.11, 12 
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Ureteral obstruction can be caused by Burkitt lymphoma that directly involves the ureter13 or by 
lymph-node metastases of other malignancies such as Kaposi sarcoma or testis tumors. Patients with 
ureteral obstruction might require ureteral stenting or percutaneous nephrostomy. The incidence of 
renal involvement in patients with non-Hodgkin lymphoma who have AIDS is 6–12%, and 
presentation can be bilateral.14, 15 
Although patients with HIV are usually excluded from dialysis and renal transplantation, there are 
now several reports in the literature of successful renal transplantation in HIV-positive recipients on 
HAART. Gruber and colleagues16 reported acute rejection rates between 43% and 67% in patients 
with renal transplants and HIV, and patient and graft survivals of 100% and 88%, respectively. 
URINARY TRACT INFECTION 
A study in the 1980s reported a 17% incidence of urinary tract infections (UTIs) in HIV-positive 
patients,17 but a study in 2003 showed that 38% of patients with HIV had a bacterial infection 
involving the lungs whereas only 5% of patients had a UTI.18 There is a greater risk of UTI when the 
CD4+ count falls below 500 cells/mm3.19, 20 
The most common bacterial cause of UTIs in patients with HIV is Enterococcus faecalis.21 Other 
pathogens that can cause UTIs in patients with HIV areEscherichia coli, Staphylococcus 
aureus, Klebsiella pneumoniae, Pseudomonas 
aeruginosa, Acinetobacter spp., Proteus spp., Staphylococcus epidermidis, group D 
streptococci, Serratia spp. and Salmonella spp.14, 15, 17, 20, 22Pathogens in the urine of HIV-infected 
patients have shown high antimicrobial resistance.23 
Atypical pathogens that have the capacity to cause a UTI in patients with HIV include fungi (Candida 
albicans, Aspergillus fumigatus, Blastomyces spp.,Cryptococcus neoformans, Cryptosporidium spp. 
and Histoplasma capsulatum), parasites (Toxoplasma gondii and Pneumocystis 
carinii),Mycobacterium spp. (Mycobacterium tuberculosis and Mycobacterium aviumcomplex) and 
viruses (cytomegalovirus and adenovirus).24, 25, 26 
In patients with AIDS and reported renal abscesses, satisfactory results have been achieved with only 
antibiotics and HAART. Percutaneous drainage of renal abscesses and appropriate cultures of 
aspirated pus are important to diagnose opportunistic infections. Nephrectomy is indicated when 
conservative therapy fails or septic shock supervenes.27 
Nosocomial infections are common in patients with HIV because central venous catheters and 
urinary catheters are often used in this patient population. Bloodstream infections are the most 
common nosocomial infection, followed by UTIs, vascular infections, and pneumonia. HIV-positive 
patients are more likely to have nosocomial infections caused by S. aureus than by any other 
pathogen.28 
BLADDER DYSFUNCTION 
Voiding disorders are usually caused by infection (e.g. cystitis or prostatitis), obstruction (e.g. of the 
bladder neck or urethra) or neurologic disorders (e.g. encephalitis, myelitis or acute idiopathic 
polyneuritis). Several unusual disorders can also cause neurogenic bladder dysfunction, such as 
herpetic ascending myelitis, cerebral toxoplasmosis and HIV encephalitis.29, 30 
Bladder outlet obstruction caused by prostatic enlargement accounts for less than 20% of cases of 
urinary retention in HIV-positive patients.29, 30, 31 As HIV survival and the mean age of patients on 
HAART increases, however, there will be an increased incidence of symptoms and complications due 
to benign prostatic hyperplasia. 
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Patients with AIDS are also at risk of developing non-Hodgkin lymphoma or rare infections of the 
bladder by T. gondii; cystoscopic bladder biopsies are needed to make the diagnosis.32 
TUBERCULOSIS 
The incidence of tuberculosis has tripled during the past two decades in countries with a high 
prevalence of HIV.33 About a third of people living with HIV worldwide are infected with tuberculosis. 
Patients who are HIV positive and are not infected with tuberculosis have a 10–15% risk of 
developing the infection.33 Tuberculosis has become the leading cause of death among HIV-positive 
patients in Africa and is the most common presenting illness among people with HIV who are taking 
HAART.34 In many developing countries, concurrent HIV and tuberculosis epidemics have 
considerably affected already poor public health services. 
Active tuberculosis might be associated with a high HIV viral load, low CD4+counts and rapid 
progression of HIV infection to AIDS.35 In patients who are immunocompromised, tuberculosis will 
usually manifest as a severe systemic infection with bacteremia, disseminated lesions and multiple 
parenchymatous renal foci.36 
Patients with AIDS who have urogenital tuberculosis (UGTB) tend to be younger than HIV-negative 
patients with UGTB (median age 26 years vs 35 years). Patients with AIDS and UGTB usually have 
fever, a high probability of parenchymatous renal involvement and disseminated tuberculosis, a low 
prevalence of storage symptoms and stenosis of the collecting system, and contracted bladder 
(Figure 1). In addition, the disease course is usually shorter in patients with AIDS who have UGTB 
than in patients with only UGTB. In patients with AIDS, UGTB often has systemic symptoms, multiple 
parenchymatous renal foci, and a low frequency of lesions of the collecting system, and can develop 
into disseminated TB.33 
Drug treatment is the first-line strategy in patients with UGTB. Treatment regimens of 6 months are 
effective in most patients.36 Patients with HIV and tuberculosis being treated with HAART should be 
carefully observed with respect to sequencing of treatment, the value of directly observed therapy, 
and the possibility of pharmacokinetic drug interactions that could result in toxicities, particularly 
hepatotoxicity and neuropathy.37, 38 
Despite effective drug therapy, surgery in the form of ablation (e.g. nephrectomy) or reconstruction 
(e.g. augmentation enterocystoplasty) might be unavoidable. Both radical and reconstructive surgery 
should be carried out after at least 2 months of intensive anti-TB drug therapy.33 
PROSTATITIS AND PROSTATIC ABSCESS 
The estimated incidence of acute bacterial prostatitis increases from 1% to 2% in the general 
population to 3% in asymptomatic HIV-positive patients and 14% in patients with AIDS.39 The 
incidence of prostatic abscesses in patients with AIDS, however, has substantially decreased with the 
advent of HAART; abscesses usually only occur in patients with very low CD4+ counts.14 
Urine culture is usually negative in men with prostatitis and AIDS, but cultures from the prostate can 
show unusual organisms such as S. aureus,Enterococcus spp., M. tuberculosis, M. 
avium, Cryptococcus spp., H. capsulatum, C. albicans, or cytomegalovirus.40, 41, 42 
CT and transrectal ultrasound of the prostate are both accurate methods of diagnosing prostatic 
disorders in patients with HIV; transrectal ultrasound is perhaps the more useful modality if 
aspiration or biopsy is required.20 A prostatic abscess can be managed with aspiration, drainage 
through the perineal route, or transurethral unroofing. Antibiotic therapy should initially include 
parenteral bactericidal agents such as broad-spectrum penicillin derivatives, third-generation 
cephalosporins with or without aminoglycosides, or fluoroquinolones.14, 20 Long-term antibiotic 
therapy is essential to avoid recurrent infection.43 
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EPIDIDYMO-ORCHITIS AND FOURNIER GANGRENE 
In sub-Saharan Africa, tuberculous epididymitis is often reported in patients with AIDS. Fungal 
infection with H. capsulatum, as well as cytomegalovirus, can involve the testis and epididymis (or 
both testes and epididymes) in HIV-positive men.44 
Fournier gangrene (necrotizing fasciitis of the external genitalia) can be the first clinical presentation 
in patients with HIV infection.6, 45, 46 Immediate diagnosis with wide surgical debridement of necrotic 
and nonviable tissue is necessary.47 Broad-spectrum antibiotic therapy for aerobic Gram-positive and 
Gram-negative bacteria, as well as for anaerobic microorganisms, is necessary while awaiting the 
results from culture and sensitivity tests.48 Hyperbaric oxygen can be useful in the treatment of 
Fournier gangrene.49 
PARASITIC INFESTATIONS 
Regions with a high prevalence of helminthic parasite infestations also have a high prevalence of HIV 
and AIDS.50 Interaction of the pathogen with host CD4+T cells is a characteristic of HIV infection as 
well as parasitic infestations, and parasitic infection can alter the disease course of tropical diseases 
such as schistosomiasis and malaria. On the other hand, tropical infections can ease transmission of 
HIV and accelerate progression from asymptomatic HIV infection to AIDS.51 
In rural Africa, women with genital schistosomiasis have a three-fold higher risk of having HIV than 
women who do not have schistosomiasis.52 In addition, HIV-positive women are more likely to have 
malaria or lymphatic filariasis than are HIV-negative women. Mother to child transmission of HIV is 
substantially more likely in women coinfected with one or more helminthic parasite than in those 
with no helminthic infection; transmission possibly takes place via a mechanism in which parasite 
antigens activate lymphocytes in utero.53 
HIV infection can hinder the diagnosis of parasitic infestations, or reduce the efficacy of antiparasitic 
treatment.51 In a study by Mwanakasale and co-workers,54 HIV-positive patients with schistosomiasis 
excreted fewer parasite eggs and had fewer symptoms of hematuria than HIV-negative patients; the 
sensitivity and positive predictive value of hematuria as an indication of substantial infection was 
lower in the group of patients coinfected with HIV. 
 
MALIGNANCIES ASSOCIATED WITH HIV AND AIDS 
AIDS-associated malignancies (AAMs) include Kaposi sarcoma, non-Hodgkin lymphoma and invasive 
cervical cancer. In the past decade there has been a significant reduction in the incidence of Kaposi 
sarcoma and non-Hodgkin lymphoma in patients with AIDS, probably as a result of HAART; the 
incidence of cervical carcinoma, however, has not decreased.55, 56, 57 On the other hand, HIV-positive 
patients still have a higher risk of developing Kaposi sarcoma and non-Hodgkin lymphoma than the 
general population.58 From 1992 to 2002, the most common malignancies in the HIV-positive 
population were Kaposi sarcoma, lymphoma (Hodgkin and non-Hodgkin), cervical cancer, liver 
cancer, testicular cancer, and melanoma.59 
In patients with HIV on HAART there has been an increase in the incidence of non-AAMs, including 
anal cancer, lung cancer, hepatocarcinoma, vaginal cancer, leukemia, oropharyngeal cancer, 
colorectal cancer, penile cancer, and renal cancer.55, 56, 57, 59, 60 
Non-AAMs—such as lung, skin, penile, laryngeal, tongue and colorectal cancer—are likely to occur at 
a younger age in HIV-positive patients than in HIV-negative individuals (47.6 years vs 60.3 years); HIV-
positive patients also seem to have a lower clinical stage of disease with these cancer types. Patients 
with HIV and a non-AAM are usually quite young at diagnosis; this fact might be partly associated 
with early detection and pre-existing immunosuppression.61 
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Possible explanations for the high prevalence of non-AAMs might include the following factors: 
longer survival of patients on HAART, with only partial immune recovery achieved in most patients; 
high incidence of human papillomavirus (HPV), Epstein–Barr virus, and hepatitis C virus coinfection in 
patients with HIV infection; and potential oncogenicity of long-term HIV infection or long-term 
HAART.62 Other proposed mechanisms of carcinogenesis include decreased immune surveillance, a 
direct effect of viral proteins, cytokine dysregulation, or other immunologic or viral cofactors.63 
The outcome for HIV-infected patients with cancer has substantially improved in the HAART era, 
probably due to the fact that the treatment considerably improves the immune status and bone 
marrow function. Current studies suggest that patients with AAMs can be treated with conventional 
modalities such as chemotherapy and radiotherapy and with appropriate use of supportive 
measures.64 
KAPOSI SARCOMA 
Kaposi sarcoma is often a presenting sign of HIV and AIDS.65 Before the advent of HAART, up to 20% 
of patients infected with HIV were affected by Kaposi sarcoma. This percentage has decreased by 
approximately 90% since the introduction of HAART.66 The cause of this rare cancer is human herpes 
virus type 8.66 Kaposi sarcoma is more common in men and usually comprises a systemic disease that 
affects internal organs, including the kidneys and testes.67 About 20% of HIV-positive men with 
Kaposi sarcoma have genital involvement, which can lead to complications such as lymphatic or 
urethral obstruction or (rarely) penile necrosis and gangrene as a result of vasculitis or vascular 
obstruction (Figure 2).68 
The first step in treatment for Kaposi sarcoma in patients with HIV is to initiate HAART or to optimize 
the HAART regimen, which generally results in remission of Kaposi sarcoma.69 Local therapy for 
cosmetically disturbing or painful lesions can include the following treatment options: laser therapy; 
cryotherapy; surgical excision; application of topical retinoids (e.g. 9-cis-retinoic acid and 
alitretinoin); use of intralesional bleomycin, interferons or vinca alkaloids; X-ray radiation; electron 
beam therapy; or cobalt radiation.66 Disseminated or visceral Kaposi sarcoma is treated with 
combination chemotherapy. The gold standard combination therapy of adriamycin, bleomycin and 
vincristine has been replaced in recent years with liposomal anthracyclines, such as daunorubicin and 
doxorubicin.69, 70 Paclitaxel is also effective in treating advanced Kaposi sarcoma.71 Suprapubic 
cystostomy might be necessary until definitive treatment takes place.72 Despite widespread 
availability of HAART and chemotherapy, Kaposi sarcoma continues to be a substantial clinical 
problem in patients with HIV, with only 50% of individuals achieving complete resolution of disease.73 
TESTICULAR TUMORS 
Early studies have suggested that the incidence of testicular tumors in immunocompromised patients 
is between 20 times and 57 times that of the general population, and that germ cell testicular tumors 
are the third most common AIDS-associated malignancy.74 Despite the high prevalence of HIV 
infection in sub-Saharan Africa, there have been no reports of a significant increase in germ cell 
testicular tumors in this region. A more recent study indicated that the relative risk for testicular 
seminoma in HIV-positive patients compared with HIV-negative individuals is around 2.75 Non-
Hodgkin lymphoma of the testes can present bilaterally and is usually disseminated at the time of 
presentation.76 Once considered to be poor candidates for radiation and chemotherapy, HIV-positive 
patients with non-Hodgkin lymphoma of the testes are currently thought to have equal morbidity 
and response to patients who do not have HIV.77 Complete remission is reported in 50–75% of 
patients with systemic treatment;78 however, the incidence of relapse and rapid progression might 
be higher in immunocompromised men than in the general population.14,15 
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PENILE CANCER 
Individuals infected with specific HPV subtypes are at risk of developing squamous cell carcinomas 
after a long period of latency (Figure 3).79 About 40–45% of patients with penile carcinoma have 
evidence of HPV DNA;80 however, factors other than HPV can also play a part in the pathogenesis of 
penile cancer.81 
Certain types of HPV are associated with squamous cell carcinoma (Figure 3). In a study of HIV-
infected men, a high prevalence of high-risk HPV types (16 and 18) was found in the anus, penis and 
mouth (78%, 36% and 30%, respectively), without evidence of pathology in these areas.82 The 
relative risk of penile cancer in HIV-positive patients is four times higher than that in HIV-negative 
men.75 
HIV-infected homosexual men have a substantially increased risk of HPV-induced anal cancer and 
anal intraepithelial neoplasia, and a moderately increased risk of penile cancer.83 In a study by 
Kreuter and colleagues84 of HIV-positive men, penile intraepithelial neoplasia was detected in 4.2% 
and anal intraepithelial neoplasia was found in 59% of these patients. Urethral and bladder 
involvement with condylomata acuminata caused by HPV is usually associated with 
immunosuppression.85 
Squamous cell carcinoma of the penis is usually more aggressive in HIV-positive patients than in 
individuals without HIV and should be excised and staged. Regional lymphadenectomy, radiation, or 
systemic chemotherapy should be used, in a similar approach to treatment for individuals not 
infected with HIV.86 
PROSTATE CANCER 
It is not clear whether there is a decreased incidence of prostate and breast cancer in HIV-positive 
patients.55, 56, 57, 59  With the increased life expectancy of HIV-positive men on HAART, however, 
prostate cancer in this population is expected to become an increasingly more important health 
problem. 
Despite a case report suggesting that prostate cancer in HIV-positive men might be unusually 
aggressive,87 prostate cancer has a similar disease course in men with HIV as that in HIV-negative 
men. With improved therapies for HIV and increasing survival, the importance of screening for and 
treating prostate cancer is increasing.88 
It has been recommended that the standard PSA assessment should be done in HIV-positive patients, 
without the need for adjustments.89 Some clinicians advocate PSA screening of HIV-positive patients 
in their early forties because of the potential for prostate cancer to present in a disseminated 
manner with nonspecific features.87, 90 
HIV-positive patients who have asymptomatic prostate cancer should be offered all possible 
treatment options, including surgery, radiation, androgen deprivation, and observation. Some 
clinicians believe that laparoscopic or robot-assisted surgery should be performed when possible to 
minimize the risk of postsurgery complications.91 In a meta-analysis of 12 publications providing 
detailed information on 60 patients with HIV and prostate cancer, early outcomes of treatment did 
not demonstrate increased acute morbidity; however, long-term outcomes have not been 
reported.88 
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 SEXUAL DYSFUNCTION AND INFERTILITY IN PATIENTS WITH HIV AND AIDS 
ERECTILE DYSFUNCTION 
Testicular atrophy is common in men with AIDS and can predispose patients to infertility, erectile 
dysfunction (ED) and reduced libido. Studies both support and oppose the occurrence of sexual 
dysfunction in HIV-positive men taking HAART.92, 93, 94, 95 Men who are HIV positive are more likely to 
have symptoms of depression than are men without HIV.96, 97  This correlation might be associated 
with low libido and ED; however, common antidepressant medications such as selective serotonin 
reuptake inhibitors can also decrease libido and sexual performance.98 Phosphodiesterase-5 
inhibitors might allow patients to recommence sexual activity and regain confidence, which can 
improve depressive symptoms.99 The use of testosterone in muscle-wasting disorders such as HIV has 
also been suggested as a treatment option.100 
Effective treatment of ED can increase the risk of spreading HIV.101 Benotschet al.102 have shown that 
men who took phosphodiesterase-5 inhibitors had higher rates of sexually risky behavior. This 
observation means that there might be an ethical dilemma in treating ED in HIV-positive 
patients.103 It is important to improve patients' quality of life, but equally important to help stop the 
spread of the virus; therefore, detailed counseling of HIV-positive men with ED is essential.104 
INFERTILITY 
Abnormal semen parameters can be associated with atrophy of the testes. Atrophy might be the 
result of hypothalamopituitary axis dysfunction, inflammation, infection, chronicity of disease, 
malnutrition, or a direct cytotoxic effect of HIV on germinal tissue.77 
If an infertile couple with one HIV-positive partner wants to have a child, the risk of HIV transmission 
has to be considered. HIV transmission rates for unprotected heterosexual intercourse are 1 case per 
1,000 contacts (male to female transmission) to less than 1 case per 1,000 contacts (female to male 
transmission).105 Sperm washing for couples where the man is infected with HIV, followed by assisted 
reproduction techniques, has proved to be the safest method for infertility treatment in HIV-positive 
couples.106, 107 Tested sperm carry a 10% risk of harboring the virus, so patients and offspring are still 
at risk; however, more than 500 children have been born after sperm washing, with no instances of 
seroconversion.105 
 
UROLOGIC COMPLICATIONS AFTER ANTIRETROVIRAL TREATMENT 
UROLITHIASIS 
Indinavir is an antiretroviral drug that works as a protease inhibitor and prevents the formation of 
new viral particles. About 20% of indinavir is not metabolized and is excreted in the urine.108, 109, 110, 111  
The drug can cause intrarenal crystal deposition, which can lead to acute renal failure.112 A total of 
80% of patients with urologic complications have raised indinavir plasma concentrations, indicating 
that plasma levels should be carefully monitored and the indinavir dosage reduced if necessary.113, 114 
Indinavir causes urolithiasis in 5–25% of HIV-positive patients treated with the 
drug.115, 116 Contributing causes of urolithiasis include diarrhea leading to dehydration, increased 
urinary concentration, acidification, and hypocitraturia.115, 117 Indinavir is reported as a stone 
component in only 29% of calculi. The remaining stone components are calcium oxalate, ammonium 
acid urate, and uric acid.115, 117 
Urolithiasis can in turn cause acute renal colic or severe azotemia. Pure indinavir stones are 
radiolucent and might escape detection by plain X-ray and CT (Figure 4).112, 115, 118, 119, 120 Treatment 
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consists of interrupting indinavir administration temporarily, giving narcotic analgesics, increasing 
oral fluid intake (until urine production reaches 2 l/day or more) and acidifying the urine by oral 
administration of the amino acid L-methionine.111, 118, 119 Double-J ureteral stents can be inserted if 
the patient experiences persistent fever or intractable pain.112 Since indinavir stones are usually 
gelatinous in consistency, extracorporeal shock wave lithotripsy will not be effective.112, 120 
 
RENAL DYSFUNCTION 
HAART regimens have a relatively low but clinically significant nephrotoxic potential.121 Acute tubular 
toxicity, crystal nephropathy, and acute interstitial nephritis are among the common renal 
manifestations of HAART nephrotoxicity. Adefovir and tenofovir are associated with tubular toxicity. 
Indinavir is associated with crystalluria, crystal nephropathy and nephrolithiasis. Acute interstitial 
nephritis has been reported in patients taking indinavir and atazanavir. Rarely, enfuvirtide can 
promote glomerulopathy. Frequent exposure to other nephrotoxic non-antiretroviral drugs (e.g. 
antibiotics, antifungals) also contributes to kidney disease.122 
 
HIV PREVENTION AND MALE CIRCUMCISION 
The mainstay of HIV prevention is the so-called ABC approach (abstinence, 'be faithful', condom use). 
Mother to child transmission can be minimized if cesarean section is performed along with 
intrapartum infusion of antiviral medications.15 
The hypothesis that uncircumcised men are at greater risk of acquiring HIV or other sexually 
transmitted infections than men who have been circumcised is based on several plausible biological 
mechanisms. These mechanisms include susceptibility of the mucosal surface of the prepuce to 
trauma, longer survival of pathogens in warm and moist subpreputial spaces, and lack of 
keratinization and high density of HIV target cells in the inner foreskin compared with the keratinized 
surface of the outer foreskin and glans.123, 124, 125, 126, 127 
Epidemiological studies in areas with a low prevalence of male circumcision and a high prevalence of 
HIV support this hypothesis.128, 129 A meta-analysis of studies that adjusted for potential confounders 
reported a large and highly significant reduced risk of HIV infection in circumcised men (adjusted risk 
ratio 0.42).123, 130 
Three prospective, randomized clinical trials of adult male circumcision in South Africa, Kenya, and 
Uganda have reported highly significant reductions in risk of HIV infection among participants 
randomly assigned to circumcision.131, 132, 133 The overall risk ratio compared with no circumcision was 
0.42 (95% CI 0.31–0.57), which corresponds with a 58% increase in protection (95% CI 43–
69%).134 Apart from absolute sexual abstinence and rigorous condom use, there is currently no 
preventive measure that has been shown to be more effective than adult male circumcision. 
 
CONCLUSIONS 
Since the advent of HAART, the prognosis of HIV-infected patients has improved dramatically and the 
life expectancy for patients with access to HAART currently seems to be similar to that of HIV-
negative individuals. Urologic complications in HIV-infected patients who receive HAART are mostly 
resultant adverse effects of treatment, in particular renal dysfunction, which is in many cases due to 
antiviral, antibacterial or antifungal medication, and urolithiasis, caused by the antiretroviral drug 
indinavir. In patients who do not have access to HAART the prognosis of HIV remains dismal, with 
eventual progression to AIDS and death being virtually inevitable. Urologic complications in patients 
with HIV are often the result of opportunistic infections by mycobacteria, parasites, fungi and viruses, 
or comprise unusual malignancies such as Kaposi sarcoma and non-Hodgkin lymphoma. Prospective 
clinical trials have conclusively shown that adult male circumcision reduces the risk of female to male 
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HIV transmission by more than 50%, which is a higher success rate than any other preventive 
measure except complete sexual abstinence, absolute monogamy or rigorous condom use. Further 
research is needed to develop preventive or curative modalities with significantly greater efficacy 
and fewer adverse effects than the currently available options. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY POINTS 
 Several regions worldwide still do not have access to 
highly active antiretroviral therapy (HAART); patients 
with HIV who do not receive HAART are at a high risk of 
developing opportunistic infections, which usually 
originate in urologic organs 
 Urologic complications are often the first clinical signs of 
HIV and AIDS 
 In patients with HIV and AIDS, urologic complications 
are typically the result of infection by mycobacteria, 
parasites, fungi and viruses 
 Urologic complications of HIV and AIDS include renal 
dysfunction, urinary tract infection, bladder dysfunction, 
urogenital tuberculosis, prostatitis, prostatic abscess, 
epididymo-orchitis, Fournier gangrene, urologic 
malignancies, sexual dysfunction and infertility 
 There is some evidence that adverse effects of HAART 
cause urologic complications such as urolithiasis and 
renal dysfunction 
 Prospective clinical trials have shown that adult male 
circumcision reduces the risk of female to male HIV 
transmission by more than 50%; however, further 
research is still needed 
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BOX 1 UROLOGIC COMPLICATIONS OF HIV AND 
AIDS. 
  
Kidneys 
 Renal dysfunction and/or renal failure 
 HIV-associated nephropathy 
 Nephrotoxicity from medication (e.g. from HAART) 
 Renal abscess 
 Renal tuberculosis 
 Urolithiasis (especially indinavir stones) 
Ureters 
 Obstruction by tuberculosis or malignancy (e.g. 
lymphoma) 
Bladder 
 Urinary tract infection by Gram-negative or Gram-
positive bacteria, or by atypical pathogens (e.g. 
mycobacteria, fungi, parasites and viruses) 
 Voiding dysfunction (caused by neurological 
disorders or bladder outlet obstruction) 
Prostate 
 Prostatitis and prostate abscess 
 Prostate cancer 
Scrotum and testes 
 Epididymo-orchitis 
 Fournier gangrene 
 Kaposi sarcoma 
 Germ cell testis tumor 
 Non-Hodgkin lymphoma 
 Hypogonadism 
 Erectile dysfunction 
 Infertility 
Penis 
 Condylomata acuminata (caused by human 
papillomavirus infection) 
 Squamous cell carcinoma 
Abbreviation: HAART, highly active antiretroviral therapy. 
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Figures 
 
Figure 1 Tuberculous pyonephrosis with widespread caseous necrosis of the renal parenchyma in an 
HIV-positive patient with a low CD4+ cell count 
 
 
Figure 2 Kaposi sarcoma causing lymphedema of the penis, scrotum and right leg due to inguino-
pelvic lymph-node metastases in an HIV-positive man 
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Figure 3 Extensive squamous cell carcinoma of the penis involving the scrotum and inguinal lymph 
nodes in an HIV-positive patient with a low CD4+ cell count 
 
 
Figure 4 Excretory urogram (intravenous pyelogram) shows filling defects in the renal collecting 
system due to urolithiasis in a patient with AIDS receiving treatment with indinavir 
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